Anti - good question but cannot give you a factual and scientific response - and no one really can other than respected authorities like FDA , Texas Heart Institute , National Health Institute and like organizations.
What we do know is that there is a critical and large unmet need (particularly Class 2 & 3 CHF patients). And based on the recent trial revision and change in endpoint , it appears that the FDA are giving TEVA all the assistance and opportunity possible (based on strong science and robust endpoints), to deliver a application that can make a difference to millions of people worldwide. With time to commercialization taking 10 years + (likely 12) + patents , any CHF successful application will be the gold standard for decade at least .
Not going to discuss the SP ( too many tactfully smart people out there who would have a more unmistakable explanation). With Nasdaq behind us (cash raised + 5/6 qrts), in my view we are now heading into a number of SP leading events including Temcell Launch Japan; RA update ; CHF interim (Teva/Msb co-update) and what we have all been waiting for.
Yeah I know - the boy that cried wolf ...BUT The Wolf, however, did truly come at last.
GLTAH
- Forums
- ASX - By Stock
- MSB
- What future CHF therapy
What future CHF therapy, page-8
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.06 |
Change
0.030(2.91%) |
Mkt cap ! $1.210B |
Open | High | Low | Value | Volume |
$1.05 | $1.09 | $1.03 | $5.796M | 5.430M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 15990 | $1.06 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.08 | 48632 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 15990 | 1.060 |
3 | 33766 | 1.055 |
2 | 38526 | 1.050 |
4 | 79050 | 1.045 |
3 | 54455 | 1.040 |
Price($) | Vol. | No. |
---|---|---|
1.075 | 48632 | 3 |
1.080 | 108135 | 6 |
1.085 | 103276 | 9 |
1.090 | 239204 | 9 |
1.095 | 74283 | 8 |
Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |